

Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer

Chitra Joseph¹, Maariya Arshad¹, Sasagu Kurozomi^{1,2}, Maryam Althobiti¹, Islam M. Miligy^{1,5}, Sara Al-izzi¹, Michael S Toss^{1,5}, Fang Qin Goh¹, Simon J Johnston¹, Stewart G Martin¹, Ian O. Ellis^{1,2}, Nigel P. Mongan^{3,4}, Andrew R. Green¹, Emad A. Rakha^{1,5}

¹Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospital NHS Trust, Nottingham, UK.

²Department of General Surgical Science, Gunma University Graduate School of Medicine, Gunma, Japan.

³Cancer Biology and Translational Research, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK

⁴Department of Pharmacology, Weill Cornell Medicine, New York, NY, 10065, USA

⁵Histopathology Department, Faculty of Medicine, Menoufia University, Egypt

Corresponding author:

Professor Emad Rakha

Department of Histopathology, Division of Cancer and Stem Cells, School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, NG5 1PB, UK

Email: Emad.Rakha@nottingham.ac.uk

Key Words: Cancer Stem Cell, invasive breast cancer, prognosis, CD133

Abstract

Purpose: CD133/ prominin 1 is a cancer stem cell marker associated with cancer progression and patient outcome in a variety of solid tumours, but its role in invasive breast cancer (BC) remains obscure. The current study aims to assess the prognostic value of CD133 expression in early invasive BC.

Methods: CD133 mRNA was assessed in the METABRIC cohort and at the proteomic level using immunohistochemistry utilising a large well-characterised BC cohort. Association with clinicopathological characteristics, expression of other stem cell markers and patient outcome were evaluated.

Results: High expression of CD133 either in mRNA or protein levels was associated with characteristics of poor prognosis including high tumour grade, larger tumour size, high Nottingham Prognostic Index, HER2 positivity and hormonal receptor negativity (all; $p < 0.001$). High CD133 expression was positively associated with proliferation biomarkers including p16, Cyclin E and Ki67 ($p < 0.01$). Tumours expressing CD133 showed higher expression of other stem cell markers including CD24, CD44, SOX10, ALDHA3, and ITGA6. High expression of CD133 protein was associated with shorter BC specific survival ($p = 0.026$). Multivariate analysis revealed that CD133 protein expression was an independent risk factor for shorter BC specific survival ($p = 0.038$).

Conclusion: This study provides evidence for the prognostic value of CD133 in invasive BC. A strong positive association of BC stem cell markers is observed at the protein level. Further studies to assess the value of stem cell markers individually or in combination in BC is warranted.

INTRODUCTION

Breast Cancer (BC) is a heterogeneous disease with significant clinical, pathological and molecular diversities between tumours. Despite improvements in early detection and management of BC, predicting outcomes remains imprecise, and for this reason many ongoing studies are now seeking to identify novel prognostic and predictive targets to improve BC treatment decision making. Cancer stem cells (CSCs), are believed to have a role in self-renewal, differentiation and carcinogenesis of a variety of malignancies [1]. Breast CSCs are proposed to have a key role in primary tumourigenesis and may also contribute to tumour heterogeneity [2,3]. *In vitro* studies using *BRCA1*-associated BC cell lines contain $CD44^+/CD24^{low}$ and $CD133^+$ cells, displayed CSC properties such as elevated rate of proliferation and tumour forming capability [4]. Evaluation of such CSC markers in BC at the protein levels such as ALDH1 and $CD44^+/CD24^{low}$ expression showed association with high histological grade, high proliferative activity and oestrogen receptor (ER) negativity [5]. Microarray gene expression data mining using $CD44^+/CD24^{low/-}$ tumour cells against normal breast epithelium resulted in the development of CSC signatures, enabling prediction of distant metastasis free survival in independent patient datasets [6,7].

CD133, also known as prominin 1, is a transmembrane protein expressed on hematopoietic stem cells. It is a putative CSC marker [4] with CD133 expressing cells possessing stem cell-like characteristics including self-renewal, high proliferation and drug-resistance; substantiating a tumourigenic role of CD133-expressing cells [8]. CD133 expression is also associated with chemotherapy resistance in tumours which might be explained by the relationship between CD133 and the upregulation of anti-apoptotic proteins such as Bcl-2 and Bcl-xL which are associated with higher levels of CD133+ in glioma stem cells [9] and are overexpressed in sub-populations of BC. Similar to neural stem cells (NSCs), CD133 positive CSC showed increased expression levels of CXCR4 which is a critical protein for the adhesion and/or migration of tumour cells, indicating an important role in migration and may play an important role in tumour invasion [10]. CD133 also plays a crucial role in cell differentiation, proliferation, apoptosis, and regulation of cancer related signaling including MAPK, PLC- β 2

and Akt pathways [11,12]. CD133 is a promising candidate for the identification of CSC in BC including aggressive HER2+ and triple-negative classes [13,14]. Reports have shown the association of CD133+CSCs with the extracellular signal-regulated kinase (ERK) signaling pathway [15] and ERK pathways are associated with increased motility, invasion and cancer progression [16]. Based on the aforementioned studies, it was hypothesised that CD133 plays an important role in BC progression and that expression might identify subgroups of BC with stem cell characteristics and poor prognosis. Thus, in this study we investigated the association between CD133 and clinicopathological factors of BC at the mRNA and protein levels in large invasive early stage BC cohorts. Because of the association of other CSC proteins with CD133, its association with other BC stem cell markers was also explored.

MATERIALS AND METHODS

Study cohort

CD133 protein expression was evaluated using a well characterised cohort of early stage primary invasive BC as previously described [17-19]. Outcome data, breast cancer-specific survival (BCSS) was maintained on a prospective basis. BCSS was defined as the interval in months from the date of primary surgery to the time of death of BC. The clinicopathological parameters for METABRIC and Nottingham series of patients are summarised in (Supplementary Table 1).

Genomic and transcriptomic analysis of CD133

The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) [20] (n=1980) was used to evaluate *CD133* mRNA expression. DNA/RNA was isolated from fresh frozen samples and genomic and transcriptional profiling were obtained using the Affymetrix SNP 6.0 and Illumina HT-12v3 platforms respectively as described previously [20,21]. The assessment of the clinicopathological impact of *CD133* transcription and its association with clinical outcome was performed by setting a cut-off point for the mRNA expression of *CD133* at the median. The clinicopathological significance of *CD133* mRNA expression using Breast Cancer Gene-Expression Miner v4.0 (bc-GenExMiner v4.0) was performed for external validation [22] as used in other published studies [23,24]. The Cancer Genome Atlas (TCGA) dataset (n=818) [25] was also used for external validation of *CD133* mRNA expression.

Immunohistochemistry

To examine CD133 expression, a rabbit monoclonal antibody against human CD133 [86781, Cell signaling, New England Biolabs (UK)] was with verification of specificity initially verified by Western blot analysis of whole cell lysates of MCF-7, MDA MB468 and SKBr3 cell lines obtained from the American Type Culture Collection; Rockville, MD, USA) using 1:1000 dilution of the primary antibody, and fluorescent secondary antibodies at (1:15000) (IR Dye 800CW donkey anti-rabbit and 680RD donkey anti-mouse, LI-COR Biosciences, UK). 5% milk (Marvel Original Dried Skimmed Milk, Premier Food Groups Ltd, St Albans, UK) was used for

blocking. Mouse β -Actin (A5441, Sigma-Aldrich; Clone AC-15; Sigma, UK) at 1:5000 was used as a house-keeping protein. A protein ladder (Page Ruler Plus Pre-Stained Protein Ladder, ThermoScientific, Waltham, MA, USA) was included. To visualise bands, fluorescence at wavelengths of 600, 700 and 800nm was used on a LiCor Odyssey Fc with image studio 4.0 (LI-COR Biosciences). The specificity of the antibody was validated by the presence of a single specific band at the predicted size (97 kDa; Fig 1a).

For evaluation of the pattern of CD133 protein expression, immunohistochemical (IHC) was initially assessed in (n=10) full-face BC tissue sections. For assessment of its expression in the whole cohort, tumour samples were arrayed onto tissue microarrays (TMAs) as previously described [17]. IHC was performed on tissue sections using the Novolink Max Polymer Detection system (Leica, Newcastle, UK). In brief, 4 μ m thick sections were deparaffinized with xylene and rehydrated through 100 % ethanol. Heat-induced retrieval of antigen epitopes was performed in citrate solution (pH 6.0) for 20 minutes using a microwave oven (Whirlpool JT359 Jet Chef 1000W). CD133 staining was performed with the rabbit monoclonal antibody [86781, Cell signaling], diluted (1:75) and incubated for overnight at 4°C. 3-3' Diaminobenzidine tetrahydrochloride (Novolink DAB substrate buffer plus) was used as the chromogen. Slides were counterstained with Novolink hematoxylin for 6 minutes, dehydrated and cover slipped.

The modified H-score method was used in assessing IHC staining, taking the staining intensity and percentage positivity into account [26]. Briefly the percentages of positively stained tumour cells for each of these intensities were subjectively estimated. Staining intensity (0–3) was multiplied by percentage (0–100) and final scores were obtained, giving a range of 0 to 300. High-resolution digital images were generated via scanning the IHC stained slides (Nanozoomer; Hamamatsu Photonics, Welwyn Garden City, UK). Staining was double scored blindly by two researchers including a histopathologist for 25% cores to assess inter-observer concordance. Moreover, the discordant cases were re-scored by the both observers and a

final score was agreed. IHC staining and dichotomisation of the other biomarkers included in this study were as per previous publications [18,27-29]. BC molecular subtypes were defined based on the IHC profile as: Luminal A: ER+/HER2- Low Proliferation (Ki67<10%), Luminal B: ER+/HER2- High Proliferation (Ki67≥10%) or ER+/HER2+, HER2-positive class: HER2+ regardless of ER status, Triple Negative (TN): ER-, progesterone receptor (PgR)- and HER2-

Statistical analysis

IBM SPSS 22.0 (Chicago, IL, USA) software was used for statistical analysis. Univariate analysis was performed using the chi-squared test to evaluate the significance of the association between expression of the biomarkers and the clinicopathological parameters of the data, as well as other previously investigated biomarkers. Spearman's correlation coefficient was carried out to examine the association between two continuous variables. Kaplan–Meier analysis with a log-rank test for significance was performed to assess BCSS. Multivariate Cox Regression analysis with adjustment of co-variables was fitted to test independence from standard prognostic factors in BC (nodal stage, tumour grade, and tumour size). P-values were adjusted using Bonferroni correction for multiple testing. A p value of < 0.05 was considered significant.

This study was approved by the Nottingham Research Ethics Committee 2 under the title 'Development of a molecular genetic classification of breast cancer'.

RESULTS

CD133 genomic profiling

High *CD133* mRNA expression was associated with high histological grade ($p < 0.0001$), triple negative ($p < 0.0001$) and HER2+ ($p = 0.004$) subtypes. High *CD133* mRNA expression was associated with negative ER and PgR status, younger age at diagnosis and premenopausal women ($p < 0.00001$; Table1). When BC was classified using the intrinsic (PAM50) subtypes, high *CD133* expression was associated with basal-like and HER2+ classes ($p < 0.0001$). Similarly, within the METABRIC Integrative Clusters, high *CD133* mRNA expression was associated with clusters 5 (ERBB2 amplified), and 10 (TNBC/basal-like) respectively ($p < 0.00001$). In the SCMGENE subtypes high *CD133* mRNA expression was associated with ER-/HER2- and HER2+ groups ($p < 0.00001$). Associations between *CD133* mRNA expression and clinicopathological variables are summarised in Table1.

Using Breast Cancer Gene-Expression Miner v4.0 high expression of *CD133* mRNA was associated with ER, and PR negative status ($n = 5222$; $p < 0.0001$; Supplementary Fig 1a-1b), higher tumour grade ($n=3294$; $p < 0.0001$; Supplementary Fig 1c) and triple negative status ($n=1191$; $p < 0.0001$; Supplementary Fig 1d). Association of *CD133* mRNA with PAM50 and SCMGENE subtypes was confirmed using the Breast Cancer Gene-Expression Miner v4.0 ($n=5263$; $p < 0.0001$; Supplementary Fig 1e-1f). The association of high *CD133* mRNA in our study was in agreement with TCGA data, (Supplementary Fig 2a-2d), younger age at diagnosis, ER->ER+ and PR->PR+, where data was available.

When considering expression of other BC stem cell (CSC) biomarker, high *CD133* mRNA showed positive correlation with previously studied CSC (Supplementary Table 2) including *CD24* ($p < 0.0001$), *CD44* ($p < 0.0001$), *SOX10* ($p < 0.0001$), *ALDHA3* ($p < 0.0001$), *ITGA6* ($p < 0.0001$), and *ALDHA1* ($p = 0.003$), while it was negatively correlated with *PTEN* ($p < 0.0001$). These associations were confirmed using Breast Cancer Gene-Expression Miner v4.0 (Supplementary Fig 3a-3d).

CD133 protein expression

CD133 protein expression showed a positive correlation with *CD133* mRNA (Spearman's coefficient 0.505; $p < 0.00001$), this association was confirmed using TCGA data (Fig 1b). Full-face tissue sections showed CD133 expression in normal glandular epithelium and DCIS is weak (Fig 1c-1d). In contrast, CD133 immunopositivity was observed in the cytoplasm / membrane of invasive cancer cells, which was stronger compared to the normal epithelial cells (Fig 1e-f), with some malignant cells featuring accumulation of CD133 expression in granules, patches and bubbles within the cytoplasm of uncertain significance (Fig 1f; Red arrows).

On TMAs, variable degree of CD133 protein expression in BC is shown in Figures 1g-1k. The H-scores of both cytoplasmic (C+) and membrane (M+) expression did not follow a normal distribution therefore for dichotomisation into low/high expression the median H score (0) was used, in agreement with previous studies [30]. H-scores for C+ and M+ staining showed a positive correlation (Spearman's coefficient 0.560; $p < 0.00001$). Of the 687 informative cores, for CD133 cytoplasmic staining, 31% of tumours showed high expression 69% displayed negative/ low expression. For the membrane staining of CD133, 14% displayed high CD133 expression of which 86% showed negative/low expression.

Similar to the mRNA observation, CD133 protein expression was also associated with poor prognostic parameters. High CD133 C+ and M+ expression was associated with higher histological grade ($p < 0.0001$), higher mitotic frequency ($p < 0.0001$; Table 2), lower tubule formation ($p = 0.015$) and higher nuclear pleomorphism ($p < 0.0001$). CD133 was highly expressed in triple negative subtype compared with non- triple negative BC ($p < 0.0001$; Table 2). Elevated CD133 M+ additionally showed association with poor NPI ($p < 0.0001$), large tumour size ($p = 0.004$), younger age at diagnosis ($p = 0.003$) and pre-menopausal status ($p = 0.009$).

High CD133 expression showed significant association with negative ER/PR status ($p < 0.0001$), and positive basal cytokeratins CK5/6, CK14 and CK17 expression (all; $p < 0.0001$; Table 3). The association between basal CKs expression and poor prognosis has been well documented [29]. High expression of CD133 was also positively associated with cell cycle regulators p16 and Cyclin E ($p = 0.0004$ and $p < 0.0001$ respectively) and proliferation marker Ki67 ($p < 0.0001$). High CD133 protein was positively associated with EGFR ($p = 0.039$) and PIK3CA ($p = 0.048$; Table 3).

Relationship between CD133 expression and other CSC markers

A significant positive correlation between CD133 C+ expression and CD24 ($p = 0.005$), CD44 ($p = 0.020$) and SOX10 ($p = 0.017$) was observed. There was a negative association between CD133 C+ and PTEN ($p = 0.009$). CD133 M+ showed a positive correlation with CD24 ($p < 0.0001$) and CD44 ($p = 0.020$; Supplementary Table 2).

CD133 expression and patient outcome

In the whole METABRIC cohort, though CD133 mRNA showed a trend of poor patient outcome it did not reach statistical significance. The 10-year BCSS of patients with tumours expressing CD133 C+ or M+ was significantly shorter than that of the low expression subgroup (HR=1.38; $p = 0.026$ and HR=1.95; $p = 0.0001$; Fig 2a-2b). Combined CD133 cytoplasmic and membrane (CM) survival analysis demonstrated that M+ expression was associated with shorter BCSS (HR=1.25; $p < 0.0001$; Fig 2c). In subgroup analysis, expression of CD133 M+ on its own and in combination with C (+/-) was predictive of shorter BCSS in the HER2+ subgroup (HR=1.96; $p = 0.04$; HR=1.29; $p < 0.001$; Fig 2e-2f respectively). There was no association between CD133 protein and outcome in Luminal A and B or TNBC (Supplementary Fig 4a-4i). In multivariate Cox regression analysis, CD133 M+ [$p = 0.038$, HR 1.4 (95% CI 1.0 – 2.1; Table 4)] and C+M+ [$p = 0.028$, HR 1.2 (95% CI 1.0 – 1.3)] protein expression was a predictor of shorter BCSS independent of tumour size [$p = 0.015$, HR 1.4 (95% CI 1.1 – 2.1)], tumour grade [$p < 0.0001$, HR 2.1 (95% CI 1.6 – 2.7)], and nodal stage [$p < 0.0001$, HR 2.2 (95% CI 1.8 – 2.8)] in the whole cohort only.

DISCUSSION

Breast cancer (BC) is a heterogeneous disease with various subtypes [31] differing in terms of morphology, molecular and biological profiles, response to therapy, clinical behavior and outcomes. Over the last decade there have been numerous studies looking into the role of CD133 as a potential prognostic marker and predictor of patient survival for various cancers including ovarian cancer, glioma and colorectal cancer [32-34]. To our knowledge, however limited research has been done to evaluate the prognostic roles of CD133 in BC [35]. Thus, the aim of the study was to determine biological and prognostic value of CD133 expression utilising large and well described BC cohorts. Both transcriptomic and proteomic results revealed that high expression of CD133 was significantly associated with poor prognostic characteristics, including high histological grade, younger age, poor NPI, ER-/PgR- tumours and histological subtypes of poor prognosis. This is in agreement with studies of other cancer sites. For example, CD133 is significantly associated with tumour aggressiveness and poor prognosis in ovarian [36], gastric [37] and renal cell carcinomas [38].

CD133 mRNA overexpression was significantly associated with TNBC as previously documented [39]. Within the METABRIC Integrative Clusters, high *CD133* mRNA expression was associated with clusters 10 (TNBC/basal-like) IC, which provides further support for a potential role in TNBC. TNBC is associated with resistance to chemotherapy and significantly correlated with worse clinical outcome [40]. The expression of CD133 has been negatively associated with $\beta 2$ isoform of the phosphoinositide-dependent phospholipase C (PLC- $\beta 2$) [13],[41] and overexpression of PLC- $\beta 2$ has a role in inducing the conversion of CD133⁺ cells to CD133⁻ cells in TNBC resulting in decrease in proliferation and invasion [42]. This implies that CD133 plays a role in tumourigenic pathways and could be a marker of poor prognosis in TNBC.

High CD133 expression was also associated with an increase in cell cycle and proliferation activity indicated by correlation with high expression of Cyclin E1, p16 and Ki67. The

proliferation-associated factor p16 is linked with ER-negative BCs and poor patient outcome [43]. The G1–S-phase transition of the cell cycle is associated with both cyclin-E and p16 [44]. The role of Cyclin E1-activated cyclin-dependent kinases (CDKs) in the proliferation of cancer stem cells is well documented [45]. Proliferation and differentiation are under control of the cell cycle and the positive association with above markers strengthens the putative role of CD133 in tumour progression.

PI3K signaling plays a crucial role in cell cycle progression, growth, and survival [46] and acts as an important mediator of self-renewal/expansion in cancer stem cells [47,48]. The PI3K pathway is regulated by EGFR, and the overexpression of EGFR in basal-like BC is activated by aberrant PI3K activity. This suggests a positive feedback loop of co-regulation. Evidence from the TCGA breast cancer study suggests that the basal-like BC subtype has the highest level of PI3K activity [25]. We observed that CD133 over-expression was positively associated with EGFR and thereby upregulating PI3K signaling. This implies that CD133 could have a role in basal-like tumourigenic pathways. Clinical trials of EGFR inhibitors highlight the need for predictive biomarkers [49] to select patients. Understanding the functional role of CD133 in regulating the EGFR/PI3K pathway in BC may have clinical application in selecting the right combination of targeted therapies, to maximise efficacy for the individual patient.

CD133 mRNA and protein expression revealed significant positive association with other key CSC markers such as CD44, CD24 and SOX10. High CD44 and CD24 expression were associated with aggressive histological features and metastasis [50,51]. The association of both of these cell surface glycoproteins with CD133 provides further support for CD133 as a marker of adverse prognosis in BC. SOX10 is a transcription factor that regulates the differentiation of neural crest cells [45]. Like CD133, SOX10 expression is associated with tumourigenicity and proliferation in melanoma [52]. Negative correlation between CD133 and the PTEN tumour suppressor was found in our study. *PTEN* loss confers increased self-renewal capacity, resulting in the development of CSC and eventually tumourigenesis. PTEN is one of the most recurrently lost or mutated tumour suppressor genes. Overexpression of

PTEN significantly decreases the levels of both CD133 mRNA and protein in glioblastoma [53,54]. Thus, in summary, evidence suggests that increased CD133 expression is associated with CSC markers and loss of a key tumour suppressor gene.

This study reveals that CD133 is associated with poor prognostic characteristics and short-term survival outcomes in BC, which is in agreement with a previous study [55]. Although CD133 C+ and CD133 M+ were both linked to shorter BCSS in the whole cohort, membrane positivity only confers the worst patient outcome. Furthermore, high CD133 membrane expression was significantly associated with younger age at diagnosis and pre-menopausal status. Positive association of CD133 and elevated levels of basal cytokeratin confers poor prognosis. CD133 mRNA and protein was also highly expressed in TNBC and HER2+, in concordance with a recent study [39]. Basal cytokeratins are strongly associated with high histological grade (III), ER-, PR- status and worse patient outcome [29]. In the whole BC cohort, CD133 M+ and C+M+ protein expression independently predicted short BCSS. Among subgroups, over-expression of CD133 protein appears to play a particularly significant role in HER2+ BC. However, due to the relatively small sample size of the HER2+ subgroup and lack of targeted treatment in the included group, further confirmation in larger cohorts of HER2+ and TNBC tumours is required alongside further functional assessment.

In conclusion, this study revealed and confirmed that elevated CD133 expression is associated with poor prognostic characteristics and poor survival outcome. Elevated expression of CD133 appears to play a role in the proliferation and progression of the aggressive HER2+ subtype of BC, and is therefore a potential therapeutic target [56]. The combination of CSC with CD133 expression may serve as a screening tool to monitor recurrence and predict prognosis which warrant further functional studies.

Acknowledgements

We thank the Nottingham Health Science Biobank and Breast Cancer Now Tissue Bank for the provision of tissue samples.

Conflict of interest

The authors have no conflicts of interest to declare.

Compliance with ethical standards

Research involving human participants

This study was approved by the Nottingham Research Ethics Committee 2 (Reference title: Development of a molecular genetic classification of breast cancer). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Abbreviations

BC: Breast cancer

BCSS: BC-specific survival

CI: Confidence intervals

ER: Oestrogen

HR: Hazard ratio

HER2: Human epidermal growth factor receptor 2

METABRIC: Molecular taxonomy of breast cancer international consortium

NPI: Nottingham Prognostic Index

PR: Progesterone

TCGA: The cancer genome atlas

FIGURE LEGENDS

Figure 1: Western blot and immunohistochemical expression of CD133 in BC. (a)

Western blotting results for CD133 expression in MCF7, MDA-MB468 and SKBr3 breast cancer cell lines using rabbit monoclonal antibody against human CD133 [86781, Cell signaling, New England Biolabs (UK)]. Green and red bands represent CD133 and Beta-Actin (house-keeping) respectively. **(b)** showing the association between CD133 mRNA and protein (TCGA). Morphological characteristics of CD133 immunohistochemistry in Full face breast cancer tissue **(c-f)**. Normal mammary gland **(c)** and DCIS **(d)** showing absent or weak CD133 staining. **(e)** showing low immunoreactivity, **(f)** Showing some area with strong intensity and red arrows represent CD133 staining as accumulated patches/ bubbles within the cytoplasm. CD133 protein expression in breast cancer TMA cores **(g-k)**. **(g)** and **(h)** showing low and high cytoplasmic (C+) expression respectively while, **(i)** and **(j)** showing low and high membrane (M+) at x40 magnification respectively. **(k)** showing the negative expression in TMA.

Figure 2: Kaplan–Meier plots of CD133 protein expression and breast cancer patient

outcome. (a) CD133 C+ vs BCSS in whole cohort, **(b)** CD133 M+ vs BCSS in whole cohort, **(c)** Combined cytoplasmic and membrane (CM) CD133 expression vs BCSS in whole cohort, **(d)** CD133 C+ vs BCSS of HER2+ tumours, **(e)** CD133 M+ vs BCSS of HER2+ tumours and **(f)** Combined cytoplasmic and membrane (CM) CD133 expression vs HER2+ tumours.

REFERENCES:

1. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. *Cancer research* 66 (19):9339-9344. doi:10.1158/0008-5472.CAN-06-3126
2. Dick JE (2003) Breast cancer stem cells revealed. *Proceedings of the National Academy of Sciences of the United States of America* 100 (7):3547-3549. doi:10.1073/pnas.0830967100
3. Joseph C, Papadaki A, Althobiti M, Alsaleem M, Aleskandarany MA, Rakha EA (2018) Breast cancer intra-tumour heterogeneity: Current status and clinical implications. *Histopathology*. doi:10.1111/his.13642
4. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L (2008) Brca1 breast tumours contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. *Breast cancer research : BCR* 10 (1):R10. doi:10.1186/bcr1855
5. Bane A, Vilorio-Petit A, Pinnaduwege D, Mulligan AM, O'Malley FP, Andrulis IL (2013) Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. *Breast cancer research and treatment* 140 (1):195-205. doi:10.1007/s10549-013-2591-1
6. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. *The New England journal of medicine* 356 (3):217-226. doi:10.1056/NEJMoa063994
7. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K (2007) Molecular definition of breast tumour heterogeneity. *Cancer cell* 11 (3):259-273. doi:10.1016/j.ccr.2007.01.013
8. Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. *Br J Cancer* 99 (8):1285-1289
9. Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ, Asadi-Lari M (2009) CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. *Cancer immunity* 9:4
10. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. *Molecular cancer* 5:67. doi:10.1186/1476-4598-5-67
11. Tabu K, Kimura T, Sasai K, Wang L, Bizen N, Nishihara H, Taga T, Tanaka S (2010) Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumour stem-like hallmarks. *Molecular cancer* 9:39. doi:10.1186/1476-4598-9-39
12. Wang YK, Zhu YL, Qiu FM, Zhang T, Chen ZG, Zheng S, Huang J (2010) Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. *Carcinogenesis* 31 (8):1376-1380. doi:10.1093/carcin/bgq120
13. Brugnoli F, Grassilli S, Piazzini M, Palomba M, Nika E, Bavelloni A, Capitani S, Bertagnolo V (2013) In triple negative breast tumour cells, PLC-beta2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness. *Molecular cancer* 12:165. doi:10.1186/1476-4598-12-165
14. Zhao P, Lu Y, Jiang X, Li X (2011) Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. *Cancer science* 102 (5):1107-1111. doi:10.1111/j.1349-7006.2011.01894.x
15. Zhu Y, Kong F, Zhang C, Ma C, Xia H, Quan B, Cui H (2017) CD133 mediates the TGF-beta1-induced activation of the PI3K/ERK/P70S6K signaling pathway in gastric cancer cells. *Oncology letters* 14 (6):7211-7216. doi:10.3892/ol.2017.7163
16. Shao GL, Wang MC, Fan XL, Zhong L, Ji SF, Sang G, Wang S (2018) Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis. *Technology in cancer research & treatment* 17:1533034617754024. doi:10.1177/1533034617754024
17. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. *International journal of cancer* 116 (3):340-350. doi:10.1002/ijc.21004

18. Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K, Reis-Filho JS, Ellis IO, Rakha EA (2012) Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. *Breast cancer research : BCR* 14 (1):R3. doi:10.1186/bcr3084
19. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. *Clinical cancer research : an official journal of the American Association for Cancer Research* 15 (7):2302-2310. doi:10.1158/1078-0432.CCR-08-2132
20. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Group M, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowitz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 486 (7403):346-352. doi:10.1038/nature10983
21. Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Borresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C (2016) The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. *Nature communications* 7:11479. doi:10.1038/ncomms11479
22. Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C, Ricolleau G, Champion L (2012) bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. *Breast cancer research and treatment* 131 (3):765-775. doi:10.1007/s10549-011-1457-7
23. Joseph C, Macnamara O, Craze M, Russell R, Provenzano E, Nolan CC, Diez-Rodriguez M, Sonbul SN, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Mukherjee A (2018) Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. *Br J Cancer* 118 (8):1142-1151. doi:10.1038/s41416-018-0041-x
24. Kurozumi S, Joseph C, Sonbul S, Gorringer KL, Pigera M, Aleskandarany MA, Diez-Rodriguez M, Nolan CC, Fujii T, Shirabe K, Kuwano H, Storr S, Martin SG, Ellis IO, Green AR, Rakha EA (2018) Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. *Breast cancer research and treatment*. doi:10.1007/s10549-018-4777-z
25. Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. *Nature* 490 (7418):61-70. doi:10.1038/nature11412
26. McCarty KS, Jr., McCarty KS, Sr. (1984) Histochemical approaches to steroid receptor analyses. *Seminars in diagnostic pathology* 1 (4):297-308
27. Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Paish EC, Macmillan RD, Ellis IO, Green AR (2010) PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. *Breast cancer research and treatment* 122 (1):45-53. doi:10.1007/s10549-009-0508-9
28. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR (2011) MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. *Breast cancer research and treatment* 127 (3):591-599. doi:10.1007/s10549-010-1028-3
29. Alshareeda AT, Soria D, Garibaldi JM, Rakha E, Nolan C, Ellis IO, Green AR (2013) Characteristics of basal cytokeratin expression in breast cancer. *Breast cancer research and treatment* 139 (1):23-37. doi:10.1007/s10549-013-2518-x
30. Li X, Zhao H, Gu J, Zheng L (2015) Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis. *International journal of clinical and experimental pathology* 8 (10):12084-12092
31. Filippini SE, Vega A (2013) Breast cancer genes: beyond BRCA1 and BRCA2. *Frontiers in bioscience* 18:1358-1372
32. Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2009) Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. *Cancer investigation* 27 (8):844-850. doi:10.1080/07357900902744502

33. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ (2011) Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. *Cancer research* 71 (11):3991-4001. doi:10.1158/0008-5472.CAN-10-3175
34. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. *Clinical cancer research : an official journal of the American Association for Cancer Research* 14 (1):123-129. doi:10.1158/1078-0432.CCR-07-0932
35. Kim SJ, Kim YS, Jang ED, Seo KJ, Kim JS (2015) Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer. *Journal of breast cancer* 18 (4):347-355. doi:10.4048/jbc.2015.18.4.347
36. Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J (2012) CD133 expression associated with poor prognosis in ovarian cancer. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* 25 (3):456-464. doi:10.1038/modpathol.2011.170
37. Hashimoto K, Aoyagi K, Isobe T, Kouhiji K, Shirouzu K (2014) Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. *Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association* 17 (1):97-106. doi:10.1007/s10120-013-0255-9
38. Saeednejad Zanjani L, Madjd Z, Abolhasani M, Andersson Y, Rasti A, Sharifabrizi A, Asgari M (2017) Cytoplasmic expression of CD133 stemness marker is associated with tumour aggressiveness in clear cell renal cell carcinoma. *Experimental and molecular pathology* 103 (2):218-228. doi:10.1016/j.yexmp.2017.10.001
39. Xia P (2017) CD133 mRNA may be a suitable prognostic marker for human breast cancer. *Stem cell investigation* 4:87. doi:10.21037/sci.2017.10.03
40. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N (2009) Triple-negative breast cancer-current status and future directions. *Annals of oncology : official journal of the European Society for Medical Oncology* 20 (12):1913-1927. doi:10.1093/annonc/mdp492
41. Bertagnolo V, Benedusi M, Querzoli P, Pedriali M, Magri E, Brugnoli F, Capitani S (2006) PLC-beta2 is highly expressed in breast cancer and is associated with a poor outcome: a study on tissue microarrays. *International journal of oncology* 28 (4):863-872
42. Brugnoli F, Grassilli S, Lanuti P, Marchisio M, Al-Qassab Y, Vezzali F, Capitani S, Bertagnolo V (2017) Up-modulation of PLC-beta2 reduces the number and malignancy of triple-negative breast tumour cells with a CD133(+)/EpCAM(+) phenotype: a promising target for preventing progression of TNBC. *BMC cancer* 17 (1):617. doi:10.1186/s12885-017-3592-y
43. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM (1998) Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. *International journal of cancer* 79 (1):71-75
44. Sher CJ (1996) Cancer cell cycle. *Science* 274:1672-1677
45. Casimiro MC, Crosariol M, Loro E, Li Z, Pestell RG (2012) Cyclins and cell cycle control in cancer and disease. *Genes & cancer* 3 (11-12):649-657. doi:10.1177/1947601913479022
46. Hemmings BA, Restuccia DF (2015) The PI3K-PKB/Akt pathway. *Cold Spring Harbor perspectives in biology* 7 (4). doi:10.1101/cshperspect.a026609
47. Li L, Xie T (2005) Stem cell niche: structure and function. *Annual review of cell and developmental biology* 21:605-631. doi:10.1146/annurev.cellbio.21.012704.131525
48. Paling NR, Wheadon H, Bone HK, Welham MJ (2004) Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. *The Journal of biological chemistry* 279 (46):48063-48070. doi:10.1074/jbc.M406467200
49. Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bholra NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL (2015) Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis

- in Basal-like Breast Cancer. *Molecular & cellular proteomics* : MCP 14 (7):1959-1976.
doi:10.1074/mcp.M115.049783
50. Bourguignon LY, Peyrollier K, Xia W, Gilad E (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumour cells. *The Journal of biological chemistry* 283 (25):17635-17651.
doi:10.1074/jbc.M800109200
51. de la Torre M, Heldin P, Bergh J (1995) Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers. *Anticancer research* 15 (6B):2791-2795
52. Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunsch J, Claudinot S, Okoniewski M, Beermann F, Mihic-Probst D, Moch H, Wegner M, Dummer R, Barrandon Y, Cinelli P, Sommer L (2012) Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. *Nature cell biology* 14 (8):882-890. doi:10.1038/ncb2535
53. Moon SH, Kim DK, Cha Y, Jeon I, Song J, Park KS (2013) PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. *International journal of oncology* 42 (3):921-928. doi:10.3892/ijo.2013.1765
54. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumour suppressor PTEN. *Cell* 95 (1):29-39
55. Liu Q, Li JG, Zheng XY, Jin F, Dong HT (2009) Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. *Chinese medical journal* 122 (22):2763-2769
56. Schmohl JU, Vallera DA (2016) CD133, Selectively Targeting the Root of Cancer. *Toxins* 8(6):165:1-19. doi:10.3390/toxins8060165

Table 1: Associations between CD133 mRNA expression and clinicopathological variables in the METABRIC cohort

Clinicopathological Criteria	CD133 mRNA expression		χ^2 & p Value
	Negative/ Low Expression N (%)	High Expression N (%)	
Age at Diagnosis			
≤50	125 (29.5)	299 (70.5)	93.529 (<0.00001)
>50	864 (55.)	687 (44.3)	
Menopause			
Pre	360 (82.6)	76 (17.4)	29.034 (<0.0007)
Post	1403 (91.5)	130 (8.5)	
Tumour Size (cm)			
≤2.0	414 (48.3)	444 (51.7)	1.921 (1.72)
>2.0	566 (51.4)	536 (48.6)	
Histological Grade			
1	88 (51.8)	82 (48.2)	23.109 (0.0001)
2	433 (56.2)	337 (43.8)	
3	425 (44.6)	527 (55.4)	
Tumour Type			
Ductal	875 (51.4)	826 (48.6)	30.186 (<0.0001)
Lobular	54 (36.7)	93 (63.3)	
Medullary-like	6 (18.8)	26 (81.3)	
Special type	33 (67.3)	16 (32.7)	
Miscellaneous	10 (47.6)	11 (52.4)	
Nottingham Prognostic Index (NPI)			
Good Prognostic Group	365 (53.7)	315 (46.3)	5.602 0.366
Moderate Prognostic Group	529 (48.0)	572 (52.0)	
Poor Prognostic Group	96(48.2)	103 (51.8)	
PAM50 subtype			
Luminal A	399 (55.6)	319 (44.4)	446.069 (<0.0001)
Luminal B	398 (81.6)	90 (18.4)	
Basal	47 (14.3)	282 (85.7)	
Her2	105 (43.8)	135 (56.3)	
Normal like	40 (2.1)	159 (79.9)	
IntClustMemb			
IntClustMemb 1	110 (79.1)	29 (20.9)	254.366 (<0.00001)
IntClustMemb 2	51 (70.8)	21 (29.2)	
IntClustMemb 3	132 (45.5)	158 (54.5)	
IntClustMemb 4	167 (48.7)	176 (51.3)	
IntClustMemb 5	65 (34.2)	125 (65.8)	
IntClustMemb 6	61 (71.8)	24 (28.2)	
IntClustMemb 7	132 (69.5)	58 (30.5)	
IntClustMemb 8	171 (57.2)	128 (42.8)	
IntClustMemb 9	71 (48.6)	75 (51.4)	
IntClustMemb 10	30 (13.3)	196 (86.7)	

SCMGENE subtypes			
<i>ER+/HER2- Low Prolif</i>	204 (55.4)	164 (44.6)	140.111 (<0.00001)
<i>ER+/HER2- High Prolif</i>	266 (72.3)	102 (27.7)	
<i>HER2+</i>	38 (34.5)	72 (65.5)	
<i>ER-/HER2-</i>	29(19.2)	122 (80.8)	
Oestrogen Receptor (ER)			
<i>Negative</i>	87 (19.8)	352 (80.2)	207.199 (<0.00001)
<i>Positive</i>	882 (58.9)	616 (41.1)	
Progesterone Receptor (PR)			
<i>Negative</i>	393 (41.8)	547 (58.2)	48.034 (<0.00001)
<i>Positive</i>	597 (57.4)	443 (42.6)	
Human epidermal growth factor receptor 2 (HER2)			
<i>Negative</i>	896 (51.7)	837 (48.3)	16.102 (0.0048)
<i>Positive</i>	94 (38.1)	153 (61.9)	
Triple Negative (TPN) status			
<i>Negative</i>	930 (56.0)	731 (44.0)	165.885 (<0.0001)
<i>Positive</i>	39 (14.1)	237 (85.9)	

Significant p values are highlighted in bold.

Table 2. Clinicopathological associations of CD133 expression in the Nottingham BC series.

Clinico pathological Criteria	CD133Cytoplasmic Staining N (%)		χ^2 & p Value	CD133 membrane Staining N (%)		χ^2 & p Value
	Negative/ Low Expression	High Expression		Negative/ Low Expression	High Expression	
Age at Diagnosis						
<50	159 (66.5)	80 (33.5)	1.673	189 (79.1)	50 (20.9)	14.152
≥50	306 (71.3)	123 (28.7)	1.97	382(89.7)	44 (10.3)	0.0030
Menopausal status						
Pre-menopause	173 (67.1)	85 (32.9)	1.389	205 (79.5)	53 (20.5)	14.796
Post-menopause	288 (71.3)	116 (28.7)	3.499	361(90.0)	40 (10.0)	0.009
Histological Grade						
1	74 (74.7)	25 (25.3)	21.463 <0.0001	96 (97.0)	3 (3.0)	57.172 <0.0001
2	167 (79.9)	42 (20.1)		202 (96.7)	7 (3.3)	
3	220 (62.0)	135 (38.0)		268 (76.1)	84 (23.9)	
Tubules						
1	21 (80.8)	5 (19.2)	13.174 0.015	24 (92.3)	2 (7.7)	29.044 <0.0001
2	162 (77.5)	47 (22.5)		200 (95.2)	10 (4.8)	
3	254 (64.1)	142 (35.9)		311 (79.1)	82 (20.9)	
Pleomorphism						
1	11 (91.7)	1 (8.3)	19.479 <0.0001	12 (100.0)	0 (0.0)	45.772 <0.0001
2	181 (78.7)	49 (21.3)		227 (97.0)	7 (3.0)	
3	244 (63.0)	143 (37.0)		301 (77.6)	87 (22.4)	
Mitosis						
1	144 (80.0)	36 (20.0)	24.727 <0.0001	176 (96.2)	7 (3.8)	49.827 <0.0001
2	104 (75.9)	33 (24.1)		129 (93.5)	9 (6.5)	
3	189 (60.2)	125 (39.8)		237 (75.2)	78 (24.8)	
IHC subtypes						
ER+/HER2-Low Proliferation	98 (79.7)	25 (20.3)	81.393 <0.0001	120 (96.0)	5 (4.0)	137.761 <0.0001
ER+/HER2-High Proliferation	166 (83.4)	33 (16.6)		191 (97.0)	6 (3.0)	
Triple Negative	48 (38.4)	77 (61.6)		63 (50.8)	61 (49.2)	
HER2+	69 (63.9)	39 (36.1)		89 (83.2)	18 (16.8)	
Histological type						
Ductal	395 (68.9)	178 (31.1)	8.095 0.484	488 (85.5)	83 (14.5)	15.771 0.008
Lobular	39 (81.3)	9 (18.7)		46 (97.9)	1 (2.1)	
Medullary-like*	8 (47.1)	9 (52.9)		10 (58.8)	7 (41.2)	
Special type	18 (78.3)	5 (21.7)		20 (87.0)	3 (13.0)	
Stage						
I	283 (68.7)	129 (31.3)	2.603 3.656	352 (86.3)	56 (13.7)	1.079 4.692
II	142 (70.3)	60 (29.7)		174 (85.3)	30 (14.7)	
III	37 (72.5)	14 (27.5)		42(84.0)	8 (16.0)	
Tumour size						
≥ 2.0cm	215 (70.7)	89 (29.3)	0.348	275 (90.2)	30 (9.8)	8.926
< 2.0cm	247 (68.6)	113 (31.4)	3.672	292 (82.0)	64 (18.0)	0.004
Nottingham Prognostic Index						
Good Prognostic Group	140 (75.7)	45 (24.3)	4.512 1.05	179 (96.8)	6 (3.2)	26.680 <0.0001
Moderate Prognostic Group	247 (67.1)	121 (32.9)		302 (82.5)	64 (17.5)	
Poor Prognostic Group	75 (67.6)	36 (32.4)		86 (78.2)	24 (21.8)	

*Significant p values are highlighted in bold.

Table 3. Associations of CD133 IHC expression and other BC related biomarkers within the Nottingham BC series.












Clinico pathological Criteria	CD133Cytoplasmic Staining		χ^2 & p Value	CD133 membrane Staining (in %)		χ^2 & p Value
	Negative/ Low expression N (%)	High expression N (%)		Negative/ Low expression N (%)	High expression N (%)	
Oestrogen (ER) status						
Negative	78 (41.7)	109 (58.3)	93.875	114 (61.6)	71 (38.4)	122.601
Positive	382 (80.3)	94 (19.7)	<0.0001	452 (95.2)	23 (4.8)	<0.0001
Progesterone (PR) status						
Negative	149 (54.4)	125 (45.6)	51.920	198 (72.5)	75 (27.5)	68.086
Positive	296 (80.9)	70 (19.1)	<0.0001	349 (95.6)	16 (4.4)	<0.0001
Human epidermal growth factor receptor 2 (HER2)						
Negative	381 (70.6)	159 (29.4)	1.717	464 (86.2)	74 (13.8)	0.624
Positive	70 (64.2)	39 (35.8)	0.210	90 (83.3)	18 (16.7)	0.451
Triple Negative						
Negative	408 (77.0)	122 (23.0)	69.726	497 (94.0)	32 (6.0)	150.358
Positive	48 (38.7)	76 (61.3)	<0.0001	63 (51.2)	60 (48.8)	<0.0001
Basal Phenotype						
Negative	368 (77.6)	106 (22.4)	53.811	436 (91.8)	39 (8.2)	47.460
Positive	90 (48.4)	96 (51.6)	<0.0001	133 (71.1)	54 (28.9)	<0.0001
Cytokeartin5/6 (CK5/6)						
Negative	328 (76.3)	102 (23.7)	39.204	391 (91.1)	38 (8.9)	78.907
Positive	40 (43.5)	52 (56.5)	<0.0001	50 (54.3)	42 (45.7)	<0.0001
Cytokeratin 14 (CK14)						
Negative	393(72.2)	151 (27.8)	17.552	469 (86.9)	71 (13.1)	4.289
Positive	34 (47.9)	37 (52.1)	<0.0001	56 (77.8)	16 (22.2)	0.073
Cytokeratin 17 (CK17)						
Negative	296 (73.3)	108 (26.7)	18.341	359 (89.1)	44 (10.9)	40.095
Positive	34 (47.9)	37 (52.1)	<0.0001	41 (59.4)	28 (40.6)	<0.0001
Epidermal growth factor receptor (EGFR)						
Negative	373 (72.0)	145 (28.0)	9.856	441 (87.5)	63 (12.5)	6.343
Positive	84 (58.3)	60 (41.7)	0.0120	113 (79.6)	29 (20.4)	0.039
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)						
Negative	89 (75.4)	29 (24.6)	3.741	456 (88.0)	62 (12.0)	6.736
Positive	278 (66.0)	143 (34.0)	0.265	115 (79.9)	29 (20.1)	0.048
Ki67						
Negative	150 (73.9)	53 (26.1)	3.388	180 (92.3)	15 (7.7)	15.182
Positive	208 (66.2)	106 (33.8)	0.316	242 (79.3)	63 (20.7)	<0.0001
p16						
Negative	258 (78.2)	72 (21.8)	35.958	301 (90.4)	32 (9.6)	13.123
Positive	112 (536)	97 (46.4)	<0.0001	165 (79.3)	43 (20.7)	0.0004
Cyclin E						
Negative	184 (71.9)	72 (28.1)	18.174	238 (93.0)	18 (7.0)	19.570
Positive	34 (45.3)	41 (54.7)	<0.0001	56 (74.7)	19 (25.3)	<0.0001







Significant p values are highlighted in bold.


Table 4: Multivariate analysis of prognostic variables and CD133 expression in relation to BCSS in the whole cohort and BC subtypes.

Variable	Whole cohort			Luminal A			Luminal B			TNBC			HER2+		
	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value
Stage	2.2	1.8-2.8	<0.001	3.3	1.3-3.3	0.002	1.8	1.2-2.6	0.005	2.0	1.3-3.3	0.002	3.2	2.1-5.0	<0.001
Grade	2.1	1.6-2.8	<0.001	1.7	0.5-22.9	0.226	1.9	1.2-3.2	0.009	3.3	0.5-22.9	0.226	2.0	0.9-4.2	0.073
Tumour size	1.4	1.1-2.1	0.015	1.4	1.1-5.5	0.034	1.3	0.7-2.4	0.349	2.4	1.1-5.5	0.034	1.3	0.7-2.5	0.335
CD133 C+	1.3	0.9-1.8	0.072	1.5	0.5-1.9	0.942	1.0	0.5-2.1	0.993	0.9	0.5-1.9	0.942	1.4	0.8-2.6	0.221
Stage	2.2	1.8-2.8	<0.001	3.5	1.5-8.5	0.005	1.8	1.25-2.6	0.004	2.0	1.3-3.2	0.002	2.0	1.3-3.2	0.002
Grade	2.1	1.6-2.8	<0.001	1.7	0.7-4.2	0.249	2.0	1.2-3.2	0.009	2.8	0.5-19.1	0.295	2.8	0.4-19.2	0.295
Tumour size	1.5	1.1-2.1	0.016	1.4	0.4-5.4	0.617	1.3	0.8-2.3	0.372	2.4	1.1-5.6	0.029	2.5	1.1-5.6	0.029
CD133 M+	1.4	1.0-2.1	0.038	2.0	0.3-16.1	0.507	0.5	0.7-3.8	0.510	1.5	0.8-2.9	0.175	1.5	0.8-2.9	0.175
Stage	2.3	1.8-2.8	<0.001	3.4	1.4-8.0	0.006	1.8	1.2-2.6	0.004	2.0	1.3-3.2	0.002	3.2	2.1-5.0	<0.001
Grade	2.1	1.6-2.7	<0.001	1.7	0.7-4.3	0.243	2.0	1.2-3.2	0.011	2.9	0.4-19.5	0.284	2.0	0.9-4.1	0.079
Tumour size	1.5	1.1-2.1	0.015	1.4	0.4-5.5	0.616	1.3	0.7-2.4	0.372	2.4	1.1-5.5	0.034	1.2	0.7-2.3	0.501
CD133 C+M+	1.2	1.0-1.3	0.028	1.3	0.7-2.7	0.409	0.9	0.5-1.5	0.674	1.1	0.9-1.4	0.317	1.2	0.9-1.6	0.103





significant p values are highlighted in bold.












Supplementary Figure 1: *CD133* gene expression and its association, using Breast Cancer Gene-Expression Miner v4.0. a) ER status, b) PR status, c) Tumour grade, d) Triple Negative status, e) PAM50 subtypes and f) SCM3 subtypes.

(a)**(b)****(c)****(d)**

Supplementary Figure 2. *CD133* gene expression and its association, using TCGA data. a) age at diagnosis, b) ER status, c) PR status and d) HER2 status.



Supplementary Figure 3. Correlation of *CD133* gene with other BCSC markers, using Breast Cancer Gene-Expression Miner v4.0 a) *CD24*, b) *CD44*, c) *SOX10* and d) *PTEN*.



Supplementary Figure 4. Kaplan–Meier plots of CD133 protein expression and breast cancer patient outcome BC subgroups. In Luminal A Tumours **a)** CD133 C+ vs BCSS, **b)** CD133 M+ vs BCSS, **c)** Combined cytoplasmic and membrane (CM) CD133 vs BCSS. Luminal B tumours **d)** CD133 C+ vs BCSS, **e)** CD133 M+ vs BCSS, **f)** Combined cytoplasmic and membrane (CM) CD133 vs BCSS. In TNBC **g)** CD133 C+ vs BCSS, **h)** CD133 M+ vs BCSS, **i)** Combined cytoplasmic and membrane (CM) CD133 vs BCSS.